Alzheimer Disease

Disease State Hub

Commentary

Sponsored

White paper

Mind the Gap: Strategies to Improve Communication Between Clinical and Nonclinical Audiences Around AAD Symptom Recognition and Diagnosis

08/21/2024

Jeff Cummings, MD, ScD; Carolyn Clevenger, DNP, RN, GNP-BC, FAANP, FGSA, FAAN; Tatyana Gurvich, PharmD, BCGP; Lakelyn Hogan Eichenberger, PhD, MA, MBA; W. Clay Jackson, MD, DipTh; Sean Tunis, MD, MSc; Kate Zhong, MD, MSc, FRCP

Agitation in Alzheimer’s dementia is a serious neuropsychiatric condition that is highly prevalent and underdiagnosed. It contributes to adverse clinical outcomes for people living with Alzheimer’s dementia...

08/21/2024

mental health

Tips From ARIC: Midlife Vascular Risk Factors Affect Alzheimer Disease Later

05/28/2019

In this commentary, Dr Rebecca Gottesman reviews the results of her ARIC-PET amyloid imaging study and explains what they mean for the future of clinical practice.

05/28/2019

For more on the etiology of Alzheimer disease content, visit our Clinical Update page

The most common type of dementia, Alzheimer disease is a progressive disease that generally begins with mild memory loss and involves parts of the brain that control thought, memory, and language.

For more Alzheimer Disease content, visit the Clinical Insights page

Brain changes may begin 10+ years before symptoms appear. These changes include buildup of proteins that form amyloid plaques and tau tangles. This causes healthy neurons to stop functioning, lose connections with other neurons, and die.

For more neurology content, visit the Resource Center

occupational therapist, neurologist, geriatrician, psychiatrist, primary care physicians, geropsychologist

For more dementia content, visit the Disease State Hub

Memory loss that disrupts daily life
Difficulty completing familiar tasks at home, at work, or at leisure
Worsening judgment
Misplacing items & failure to retrace steps
Changes in mood, personality, or behavior

For more imaging content, visit the Resource Center

There is no single test to determine AD, but testing options include: computed tomography scan, magnetic resonance imaging, positron emission tomography scan, cerebrospinal fluid analysis, neurological examination

For more neurological diseases content, visit the Disease State Hub

Examples of cognitive, functional, and behavioral tests include: Ascertain Dementia 8, Activities Questionnaire, Mini-Cog Mini-Mental State Examination, Montreal Cognitive Assessment, Neuropsychiatric Inventory Questionnaire

For more traumatic brain injury content, visit the Resource Center

Age
Family history
Genetics
Mild cognitive impairment
Modifiable risk factors, like obesity, high cholesterol, poorly controlled type 2 diabetes

For more polls and quizzes, visit the interactive features page

An estimated 6.7 million Americans aged 65 years or older are living with AD (73% are aged 75 years or older)

For more patient education content, visit the Resource Center

By 2025, the number of people aged 65 or older with AD is projected to reach 7.2 million — a 7% increase from 2023.

November 2024

Current Issue

November 2024

Sources

CDC.gov
2023 Alzheimer's Facts and Figures